Blood biomarkers for Alzheimer's disease in clinical practice and trials

O Hansson, K Blennow, H Zetterberg, J Dage - Nature aging, 2023‏ - nature.com
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Neurofilaments as biomarkers in neurological disorders—towards clinical application

M Khalil, CE Teunissen, S Lehmann, M Otto… - Nature Reviews …, 2024‏ - nature.com
Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-
axonal injury. The advent of highly sensitive analytical platforms that enable reliable …

Plasma proteomic profiles predict future dementia in healthy adults

Y Guo, J You, Y Zhang, WS Liu, YY Huang, YR Zhang… - Nature Aging, 2024‏ - nature.com
The advent of proteomics offers an unprecedented opportunity to predict dementia onset.
We examined this in data from 52,645 adults without dementia in the UK Biobank, with 1,417 …

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

CE Teunissen, IMW Verberk, EH Thijssen… - The Lancet …, 2022‏ - thelancet.com
For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Blood‐based biomarkers for Alzheimer's disease

A Leuzy, N Mattsson‐Carlgren, S Palmqvist… - EMBO molecular …, 2022‏ - embopress.org
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

S Palmqvist, P Tideman, N Cullen, H Zetterberg… - Nature medicine, 2021‏ - nature.com
A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might
provide accurate prediction about the risk of develo** Alzheimer's disease (AD) dementia …

Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies

A Yuan, RA Nixon - Frontiers in neuroscience, 2021‏ - frontiersin.org
Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

N Kanberg, NJ Ashton, LM Andersson, A Yilmaz… - Neurology, 2020‏ - neurology.org
Objective To test the hypothesis that coronavirus disease 2019 (COVID-19) has an impact
on the CNS by measuring plasma biomarkers of CNS injury. Methods We recruited 47 …

Serum neurofilament light levels in normal aging and their association with morphologic brain changes

M Khalil, L Pirpamer, E Hofer, MM Voortman… - Nature …, 2020‏ - nature.com
Neurofilament light (NfL) protein is a marker of neuro-axonal damage and can be measured
not only in cerebrospinal fluid but also in serum, which allows for repeated assessments …

Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls

F Bavato, C Barro, LK Schnider, J Simrén… - Molecular …, 2024‏ - nature.com
The recent introduction of new-generation immunoassay methods allows the reliable
quantification of structural brain markers in peripheral matrices. Neurofilament light chain …